Cue Biopharma announced on April 8, 2026, at 8:00 a.m. ET that it will receive a $7.5 million payment from its collaboration and license agreement with Boehringer Ingelheim. This follows BI’s selection and approval of the first compound for lead optimization of CUE-501, a bispecific molecule for targeted B cell depletion in autoimmune and inflammatory diseases. The payment is expected in May 2026. The multi-year deal offers potential for up to ~$337.5 million in additional research, development, and commercial milestones plus royalties on net sales, with scope to expand into additional B cell-targeting bispecifics. This provides non-dilutive capital and external validation of the platform at a time when the company is also advancing its lead asset CUE-401 toward the clinic (following an R&D Day event the prior day). Trading volume surged dramatically (over 74 million shares, more than 11x the recent average), confirming strong investor reaction to the news.
https://finviz.com/quote.ashx?t=CUE&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.